Use of taurolidine and/or taurultam for treatment of abdominal cancer and/or for the prevention of metastases

• US 20020091123A1
• Filed: 10/09/2001
• Published: 07/11/2002
• Est. Priority Date: 07/31/1998
• Status: Active Grant

• Current Assignee: ED. Geistlich Soehne AG Fuer Chemische Industrie
• Original Assignee: ED. Geistlich Soehne AG Fuer Chemische Industrie
• Inventors: Redmond, H. Paul, Pfirrmann, Rolf W.
• Granted Patent: US 7,151,099 B2
• Time in Patent Office: Days
• US Class Current: 514/222.5
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/54 having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame

Abstract

Taurolidine and/or taurultam is administered during and after surgical removal of a cancerous tumor to treat abdominal cancer.

Claims

1. A method of treating abdominal cancer comprising performing a surgery on a patient'"'"'s abdomen by forming a surgical opening in said patient'"'"'s abdomen, surgically removing a cancerous tumor from the patient'"'"'s abdomen through the surgical opening, and closing said surgical opening, the method including a step of administering taurolidine, taurultam or a mixture thereof to the patient'"'"'s abdomen prior to said closing of said surgical opening and after said surgically removing said cancerous tumor, so as to treat cancer in the patient'"'"'s abdomen, further including a step of additionally administering taurolidine, taurultam or a mixture thereof to said patient after said closing said surgical opening.

2. The method of claim 1 wherein, after closing said surgical opening, said taurolidine, taurultam or mixture thereof is administered to said patient by installation or intravenous infusion.

3. The method of claim 2, further including the step of additionally administering taurolidine, taurultam or a mixture thereof to said patient prior to forming said surgical opening in said patient'"'"'s abdomen.

4. The method of claim 1, further including the step of additionally administering taurolidine, taurultam or a mixture thereof to said patient prior to forming said surgical opening in said patient'"'"'s abdomen.

5. The method of claim 1, wherein performing said surgery on said patient includes introducing a trocar tube into said patient during laparoscopic tumor surgery so as to conduct laparoscopic tumor surgery utilizing said trocar tube.

6. The method of claim 5 wherein during said surgery, said administering said taurolidine, taurultam or mixture thereof to said patient'"'"'s abdomen is conducted by passing a solution containing said taurolidine, taurultam or mixture thereof through said trocar tube so as to contact internal tissue of the patient with said solution.

7. The method of claim 6 further comprising the step of withdrawing said trocar tube from said patient prior to said closing said surgical opening and prior to said step of additionally administering said taurolidine, taurultam or mixture thereof to said patient after closing said surgical opening.

8. The method of claim 1 wherein said taurolidine, taurultam or a mixture thereof is present in a solution containing from 0.5 to 3% by weight said taurolidine or from 2 to 3% by weight said taurultam, or a mixture thereof.

9. The method of claim 8 wherein said solution further contains heparin, a heparin derivative or hyaluronic acid.

10. The method of claim 6 further comprising the step of additionally introducing said solution into said patient prior to said laparoscopic tumor surgery and prior to introducing said trocar tube into said patient.

11. The method of claim 5 wherein said cancerous tumor is selected from the group consisting of oesophagus carcinoma, cardiacarcinoma, malignant degenerative ulcus, stomach carcinoma, antrum carcinoma, corpus carcinoma, malign adenoma of island cells, gall duct carcinoma, distal choledochus carcinoma, pancreas head carcinoma, pancreas papilla carcinoma, pancreas corpus carcinoma, pancreas cauda carcinoma, small intestinal tract carcinoma, large intestinal tract carcinoma, sarcoma, colon malignancy, adeno carcinoma, lymphoma, malign carcinoid, melanoma, rectal carcinoma, ovarial carcinoma, mamma carcinoma, and prostate carcinoma.

12. The method of claim 1 wherein said cancerous tumor is selected from the group consisting of colon cancer, rectal cancer, pancreatic cancer, stomach cancer and lung cancer.